Elkedonia
Discovery1 active candidate
same indication: Major Depressive Disorder (MDD)Discovery peersame regulator: EU EMAsimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Discovery
Biomia
CategoriesEarly-Stage Translational Research (Pre-Clinical)Research, Drug Development & Manufacturing
Data updated
1 Drug Candidate
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Biomia is a Copenhagen-based synthetic biology company developing novel plant-inspired drug candidates for unmet medical needs in pain, addiction, and depression. Using a proprietary AI-assisted drug discovery engine and fermentation-based biomanufacturing platform, the company engineers Monoterpene Indole Alkaloid (MIA) derivatives — a large family of plant-derived bioactive compounds including ibogaine analogs — with optimised halogenation to improve ADME properties and therapeutic profiles.
Ecosystem
2 connectionsInvestors
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Discovery
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Biomia - AI and Yeast-Based CNS Drug Discovery
Jun 26, 2026 - company-website - Biomia - MIA Drug Discovery Platform
Next known catalyst
candidate-selection
Timing not specified - MIA Drug Discovery Platform / MIA Neuroplastogen Discovery Platform (Yeast Biomanufacturing) - Confidence: 25%
4 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
1MIA Drug Discovery Platform
Discovery
CNS disorders (pain, mental health, addiction, schizophrenia) — monoterpene indole alkaloid candidates via yeast biomanufacturing
Major Depressive Disorder (MDD)
Primary: EU (EMA)
DiscoveryActive
Forecast
candidate-selection
Discovery-stage platform remains active; Biomia announced an IRLAB collaboration in January 2026 to evaluate drug candidates using IRLAB's Integrative Screening Process.
Milestones
Company milestone
CompletedActual: Jan 1, 2022
Biomia founded in Copenhagen; spun out of EU MIAMI project ($10M) and Bio-Innovation Institute ($3M grant) research
Why it matters: Biomia's yeast biomanufacturing platform covers the broader monoterpene indole alkaloid (MIA) class — ibogaine, yohimbine, stemmadenine, and novel analogues. This is a broader approach than single-compound ibogaine companies. Copenhagen synthetic biology ecosystem (DTU/UCPH) is a strength.
Funding milestone
CompletedActual: Sep 1, 2023
$3M pre-seed raised led by BlueYard Capital, with Amino Collective and Nucleus Capital
Why it matters: BlueYard Capital (European deep-tech VC) led the pre-seed, validating the biomanufacturing platform approach. $3M is modest but appropriate for discovery-stage synthetic biology.
Watch next: Second fundraising round and first candidate nomination
Company milestone
CompletedActual: May 1, 2025
Frederick Westhorpe appointed CSO; co-founder Jie Zhang transitioned to CTO
Why it matters: Dedicated CSO appointment signals progression from academic platform work to directed drug discovery. Team expansion supports first candidate nomination.
Recorded Events
May 1, 2025: Company milestone
Sep 1, 2023: Funding milestone
Jan 1, 2022: Company milestone
Evidence Links
Biomia - AI and Yeast-Based CNS Drug Discovery
company-website - Biomia - Jun 26, 2026 - Verified
Company site describes AI-driven discovery and yeast-based biomanufacturing for novel CNS therapeutics.
Biomia Secures 3.0M Pre-Seed Financing
Press release - Biomia - Jan 1, 2023 - Verified
Financing announcement supports the plant-inspired and new-to-nature halogenated small-molecule pipeline.
IRLAB Enters Collaboration Agreement with Biomia
partner-announcement - IRLAB Therapeutics - Jan 19, 2026 - Verified
Recent collaboration will evaluate Biomia drug candidates using IRLAB Integrative Screening Process.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Entheos Labs
Discovery1 active candidate
same indication: Major Depressive Disorder (MDD)Discovery peersimilar active pipeline sizeboth have forecast coverage
Equulus Therapeutics
Preclinical2 active candidates
2 shared indicationssimilar active pipeline sizeboth have forecast coverageboth have source coverage
CB Therapeutics
Discovery2 active candidates
same indication: Major Depressive Disorder (MDD)Discovery peersimilar active pipeline sizeboth have forecast coverage
Quick Facts
- Type
- Private Biotech
- Founded
- 2022
- Lead Stage
- Discovery
- Website
- Visit